Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs" is generating significant coverage in the Health category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include CFO.com, Darwin Nutrition, The Globe and Mail and The Union Democrat. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 105d ago.
Quick answers
Why is "Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (10)
- As many Mass. residents face losing access to GLP-1s, local researchers dig into mental, physical impacts The Bay State Banner · 105d ago
- As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner The Globe and Mail · 105d ago
- GLP-1 Access Depends on Smarter Benefit Design and Patient Support Pharmacy Times – Pharmacy Practice News and Expert Insights · 105d ago
- Soaring demand for GLP-1 drugs strains city budgets in North Texas, causing cuts WFAA · 105d ago
- Medicaid drops GLP-1 coverage for tens of thousands in Mass., including children The Boston Globe · 105d ago
- High cost of GLP-1 drugs tries companies’ patience CFO.com · 105d ago
- Ozempic and GLP-1 reimbursement in 2026: who is eligible? Darwin Nutrition · 105d ago
- As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner The Globe and Mail · 105d ago
- Trouble getting weight loss drugs covered by insurance? Here’s what to know The Union Democrat · 105d ago
- Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs CNBC · 105d ago
Topics
Related trends
Tests of Unapproved Weight- Loss Drug Reveal Its Dangers
Laboratory tests and AI analysis reveal severe dangers tied to the unapproved weight-loss drug retatrutide.
Healthy Thunder make their statement, beat Spurs 116-104 in season opener
2 news sources are covering this Sports story right now — PULSE is tracking how fast it spreads.
Is my GLP-1 safe? What to know about FDA's crackdown on copycat drugs
FDA moves to curb bulk compounding of GLP‑1 weight‑loss drugs as legal action hits telehealth firm HIMS
Millions of Surgery Records Raise New Questions About GLP-1 Drugs
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
GLP-1 injections recalled nationwide. See affected products
19 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Barbara Palvin Returns to Victoria's Secret Fashion Show 2026 One Month After Giving Birth
Barbara Palvin returned to the Victoria's Secret Fashion Show runway shortly after giving birth, drawing widespread media attention.